首页> 外文期刊>Angiogenesis >Statin-AE: a novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity.
【24h】

Statin-AE: a novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity.

机译:Statin-AE:一种具有增强的抗血管生成和抗肿瘤活性的新型血管抑素-内皮抑素融合蛋白。

获取原文
获取原文并翻译 | 示例
       

摘要

The combination of angiostatin and endostatin has been shown to have synergistic antiangiogenic and antitumor effects when the genes for these proteins are delivered to tumor cells by retroviral gene transfer. Here we report the construction of a murine angiostatin-endostatin fusion gene (Statin-AE) which shows enhanced antiangiogenic activity on human umbilical vein endothelial cell (HUVEC) tube formation in vitro compared with angiostatin or endostatin alone. Similarly, the fusion gene demonstrates antiangiogenic effects in vivo and antitumor activity in a B16F10 melanoma model when co-delivered by retroviral packaging cell inoculation in mice. The fusion gene demonstrates significantly greater inhibition of tumor growth compared with angiostatin, endostatin or the combination of genes.
机译:当通过逆转录病毒基因转移将这些蛋白质的基因递送至肿瘤细胞时,已证明血管抑素和内皮抑素的组合具有协同的抗血管生成和抗肿瘤作用。在这里,我们报告的小鼠血管抑制素-内皮抑素融合基因(Statin-AE)的构建与单独的血管抑制素或内皮抑素相比,在体外对人脐静脉内皮细胞(HUVEC)管的形成具有增强的抗血管生成活性。同样,当在小鼠中通过逆转录病毒包装细胞接种共同递送时,融合基因在B16F10黑色素瘤模型中显示出体内抗血管生成作用和抗肿瘤活性。与血管抑素,内皮抑素或基因组合相比,融合基因显示出对肿瘤生长的抑制作用明显更大。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号